PA Capital’s ADMA Biologics ADMA Stock Holding History

PA Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$84K	Sell	35,337 -49,459	-58%	-$136K	0.06%	170
2020 Q2	$248K	Buy	84,796 +1,632	+2%	+$4.69K	0.18%	133
2020 Q1	$240K	Buy	+83,164	New	+$287K	0.21%	126
2019 Q4	–	Sell	-33,271	Closed	-$148K	–	132
2019 Q3	$148K	Buy	33,271 +22,629	+213%	+$94.6K	0.15%	111
2019 Q2	$41K	Buy	+10,642	New	+$47K	0.04%	106

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PA Capital's ADMA Position: Q3 2020 in Review

PA Capital reduced its ADMA Biologics (ADMA) stake by 58% in Q3 2020, selling an estimated $136K and leaving 35,337 shares worth $84K. The position accounts for 0.06% of the portfolio, ranked #170.

PA Capital first reported a position in ADMA in Q2 2019 and has held it in 5 quarters since. The position peaked at $248K in Q2 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q3 2020.

PA Capital held 35,337 shares of ADMA Biologics worth $84K as of Q3 2020.
PA Capital sold 49,459 ADMA Biologics shares in Q3 2020, an estimated $136K.
ADMA Biologics made up 0.06% of PA Capital's portfolio in Q3 2020, its #170 holding.
PA Capital first reported a position in ADMA Biologics in Q2 2019 and has held it in 5 quarters since.
PA Capital's ADMA Biologics position peaked at $248K in Q2 2020.
95 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.